Syed Asim Ali Shah
Research Subjects
Syed Asim Ali Shah has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Nadeem
Department of Medicine, Poonch Medical College, Rawalakot, Rawalakot, Pakistan
2 shared publications - Anum Afsar
Medicine, Wah Medical College, Wah Cantt, PAK
1 shared publication Faiza Riaz
Medicine, Wah Medical College, Wah Cantt, PAK
1 shared publication- Muzamil Jameel
Medicine, Wah Medical College, Wah Cantt, PAK
1 shared publication Nasir Khan
Medicine, Wah Medical College, Wah Cantt, PAK
1 shared publicationNazia Bano
Biotechnology, International Islamic University, Islamabad, PAK
1 shared publication
Latest Publications
- Open Access
- 29 November 2020
- Published by Springer Nature in Cureus
- Vol. 12 (11)
Antimicrobial Sensitivity Pattern of Salmonella Typhi: Emergence of Resistant Strains
Typhoid fever is still an important public health problem in developing countries. Increasing resistance of Salmonella Typhi to antibiotics is alarming. New extensively drug-resistant strains of Salmonella reported first time in Pakistan, resistant not only to first-line drugs and ciprofloxacin but also resistant to ceftriaxone, had spread globally, including the USA. Due to this continuously changing pattern of antimicrobial resistance in typhoid fever due to Salmonella Typhi, there is a substantial need to study the resistance pattern of Salmonella Typhi frequently in different areas to detect the new resistant strains timely. The objective of this study was to evaluate the current trends in the resistance pattern of Salmonella Typhi in a tertiary care hospital in Northern Punjab. This cross-sectional study was conducted at the Department of Medicine, Pakistan Ordnance Factories (POF) Hospital Wah Cant in collaboration with the Department of Pathology, from 1st January 2019 to 30th September 2019. Culture-positive patients of typhoid fever age more than 12 years, either male or female, were included in the study. The antimicrobial susceptibility of the isolates was determined by the disc diffusion method of Kirby Bauer on Mueller-Hinton agar using Clinical Laboratory Standards Institute (CLSI) guidelines. The antimicrobial agents tested were ampicillin (10 μg), chloramphenicol (30 μg), trimethoprim/sulfamethoxazole (1.25/23.75 μg), ciprofloxacin (5 μg), ceftriaxone (30μg), azithromycin (15μg), imipenem (10μg) and meropenem (10μg). A total of 81 culture-positive patients were included in the study. Out of these, 59% were male, and 41 % were female. Mean age was 23.8±19.1 years ranging from 12 to 91 years. Salmonella Typhi showed the highest sensitivity to imipenem 100% and azithromycin 95%; the lowest sensitivity was to ciprofloxacin 3.7%. Almost 50% of patients were resistant to ceftriaxone, and 48% were resistant to meropenem. The number of multidrug-resistant cases reported was 20%, whereas 47% of strains were extensively drug-resistant. Resistance to antimicrobial agents is increasing in patients with typhoid fever due to Salmonella Typhi; especially the extensively drug-resistant strains of Salmonella Typhi are increasing rapidly. New emerging strains resistant to carbapenems found in our study are a big threat. Prescription of antibiotics according to culture and sensitivity for sufficient duration in patients of typhoid fever due to Salmonella Typhi is necessary to prevent the emergence of new resistant strains.
- 29 November 2020
- Published by Springer Nature in Cureus
- Vol. 12 (11)
Open AccessAntimicrobial Sensitivity Pattern of Salmonella Typhi: Emergence of Resistant Strains
Typhoid fever is still an important public health problem in developing countries. Increasing resistance of Salmonella Typhi to antibiotics is alarming. New extensively drug-resistant strains of Salmonella reported first time in Pakistan, resistant not only to first-line drugs and ciprofloxacin but also resistant to ceftriaxone, had spread globally, including the USA. Due to this continuously changing pattern of antimicrobial resistance in typhoid fever due to Salmonella Typhi, there is a substantial need to study the resistance pattern of Salmonella Typhi frequently in different areas to detect the new resistant strains timely. The objective of this study was to evaluate the current trends in the resistance pattern of Salmonella Typhi in a tertiary care hospital in Northern Punjab. This cross-sectional study was conducted at the Department of Medicine, Pakistan Ordnance Factories (POF) Hospital Wah Cant in collaboration with the Department of Pathology, from 1st January 2019 to 30th September 2019. Culture-positive patients of typhoid fever age more than 12 years, either male or female, were included in the study. The antimicrobial susceptibility of the isolates was determined by the disc diffusion method of Kirby Bauer on Mueller-Hinton agar using Clinical Laboratory Standards Institute (CLSI) guidelines. The antimicrobial agents tested were ampicillin (10 μg), chloramphenicol (30 μg), trimethoprim/sulfamethoxazole (1.25/23.75 μg), ciprofloxacin (5 μg), ceftriaxone (30μg), azithromycin (15μg), imipenem (10μg) and meropenem (10μg). A total of 81 culture-positive patients were included in the study. Out of these, 59% were male, and 41 % were female. Mean age was 23.8±19.1 years ranging from 12 to 91 years. Salmonella Typhi showed the highest sensitivity to imipenem 100% and azithromycin 95%; the lowest sensitivity was to ciprofloxacin 3.7%. Almost 50% of patients were resistant to ceftriaxone, and 48% were resistant to meropenem. The number of multidrug-resistant cases reported was 20%, whereas 47% of strains were extensively drug-resistant. Resistance to antimicrobial agents is increasing in patients with typhoid fever due to Salmonella Typhi; especially the extensively drug-resistant strains of Salmonella Typhi are increasing rapidly. New emerging strains resistant to carbapenems found in our study are a big threat. Prescription of antibiotics according to culture and sensitivity for sufficient duration in patients of typhoid fever due to Salmonella Typhi is necessary to prevent the emergence of new resistant strains.
- Open Access
- 2 September 2020
- Published by Springer Nature in Cureus
- Vol. 12 (9)
Oral Erythromycin Improves the Quality of Endoscopy in Upper Gastrointestinal Bleeding Patients
Upper gastrointestinal bleeding is a life-threatening emergency. Endoscopy is the therapeutic and diagnostic procedure of choice after initial stabilization of the patient. But the presence of retained blood, blood products, and other residual material in the stomach is a big challenge for endoscopists during urgent endoscopy after acute upper gastrointestinal bleeding. Intravenous erythromycin before endoscopy improves the visualization of gastric and duodenal mucosa in these patients. Use of oral erythromycin is more easy and convenient, so the objective of our study was to assess the effects of oral erythromycin on quality of endoscopy in upper gastrointestinal bleeding patients. This interventional study was conducted at the Department of Medicine, POF Hospital Wah Cantt, Pakistan from January 2019 to December 2019. Patients with clinical evidence of acute upper gastrointestinal bleeding within 12 hours were inducted consecutively. Patients were randomly assigned to erythromycin (500 mg) suspension or placebo, orally three hours before endoscopy. One endoscopist performed all the procedures with the same double-channel video endoscope. The primary endpoint was endoscopic quality. The secondary endpoints were the need for second-look endoscopy within 48 hours, endoscopy related complications, therapeutic procedure performed or not during endoscopy, number of blood transfusions, and length of hospital stay. A total of 60 patients were included in the study; 30 received erythromycin and 30 received placebo. Out of these, 60% were male and 40% were female. The mean age was 53.68 ± 16.64. Quality of endoscopy was much better in the erythromycin group (83.3%) as compared to placebo (40%). Erythromycin did not shorten the endoscopic duration (15.53 vs. 14.33 minutes in the placebo group; p=0.216) and length of hospital stay (5.23 in erythromycin vs. 5.40 days in placebo group; p=0.807). Statistically no significant association was found between use of erythromycin and establishment of cause of bleed, need for second-look endoscopy, number of blood transfusions and number of endoscopic therapeutic procedures. Erythromycin oral suspension before endoscopy in patients with acute upper gastrointestinal bleeding produced good quality of endoscopy in our study. It improved the visualization of gastric and duodenal mucosa significantly. However, it did not shorten the duration of endoscopy or hospital stay. There was no significant difference in number of second-look endoscopies and blood transfusions as well.
- 2 September 2020
- Published by Springer Nature in Cureus
- Vol. 12 (9)
Open AccessOral Erythromycin Improves the Quality of Endoscopy in Upper Gastrointestinal Bleeding Patients
Upper gastrointestinal bleeding is a life-threatening emergency. Endoscopy is the therapeutic and diagnostic procedure of choice after initial stabilization of the patient. But the presence of retained blood, blood products, and other residual material in the stomach is a big challenge for endoscopists during urgent endoscopy after acute upper gastrointestinal bleeding. Intravenous erythromycin before endoscopy improves the visualization of gastric and duodenal mucosa in these patients. Use of oral erythromycin is more easy and convenient, so the objective of our study was to assess the effects of oral erythromycin on quality of endoscopy in upper gastrointestinal bleeding patients. This interventional study was conducted at the Department of Medicine, POF Hospital Wah Cantt, Pakistan from January 2019 to December 2019. Patients with clinical evidence of acute upper gastrointestinal bleeding within 12 hours were inducted consecutively. Patients were randomly assigned to erythromycin (500 mg) suspension or placebo, orally three hours before endoscopy. One endoscopist performed all the procedures with the same double-channel video endoscope. The primary endpoint was endoscopic quality. The secondary endpoints were the need for second-look endoscopy within 48 hours, endoscopy related complications, therapeutic procedure performed or not during endoscopy, number of blood transfusions, and length of hospital stay. A total of 60 patients were included in the study; 30 received erythromycin and 30 received placebo. Out of these, 60% were male and 40% were female. The mean age was 53.68 ± 16.64. Quality of endoscopy was much better in the erythromycin group (83.3%) as compared to placebo (40%). Erythromycin did not shorten the endoscopic duration (15.53 vs. 14.33 minutes in the placebo group; p=0.216) and length of hospital stay (5.23 in erythromycin vs. 5.40 days in placebo group; p=0.807). Statistically no significant association was found between use of erythromycin and establishment of cause of bleed, need for second-look endoscopy, number of blood transfusions and number of endoscopic therapeutic procedures. Erythromycin oral suspension before endoscopy in patients with acute upper gastrointestinal bleeding produced good quality of endoscopy in our study. It improved the visualization of gastric and duodenal mucosa significantly. However, it did not shorten the duration of endoscopy or hospital stay. There was no significant difference in number of second-look endoscopies and blood transfusions as well.